🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +9.56% on $DUOL.RTH in just 96h 1m.
RLM
Relmada Therapeutics Inc
AVG HISTORICAL GAP
-0.42%
MAX GAP RECORD
-8.71%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $RLMD
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$RLMD
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Aug 06, 2026 Earnings Release 2026-08-06 (AFTER CLOSE) |
+1.40%
|
| Mar 19, 2026 Earnings Release 2026-03-19 (AFTER CLOSE) |
+4.00%
|
| Nov 13, 2025 Earnings Release 2025-11-13 (AFTER CLOSE) |
-8.71%
|
| May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE) |
-3.02%
|
| Mar 27, 2025 Earnings Release 2025-03-27 (AFTER CLOSE) |
+4.36%
|
| Nov 07, 2024 Earnings Release 2024-11-07 (AFTER CLOSE) |
-0.31%
|
| Aug 07, 2024 Earnings Release 2024-08-07 (AFTER CLOSE) |
-0.93%
|
| May 07, 2024 Earnings Release 2024-05-07 (AFTER CLOSE) |
-0.79%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
2.4%
Bullish Gaps (4)
Bearish Gaps (4)
Neutral / Flat (5)
📖 Intelligence Summary
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31,…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗